Eli Lilly and Company has announced that its Phase 3 RELAY study of CYRAMZA (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement in the time patients lived without their cancer growing or spreading after starting treatment.
Tenax Therapeutics announced that the first patient has been randomized for its phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).
Gilead Sciences has announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for potential future use as part of long-acting HIV combination therapy.
ViiV Healthcare presented comprehensive 48-week data from the ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) pivotal phase III studies of the novel, investigational, long-acting regimen of cabotegravir and rilpivirine.
A second person has experienced sustained remission from HIV-1 after ceasing treatment, reports a paper led by UCL and Imperial College London.
Novo Nordisk’s Ozempic (semaglutide), in combination to SGLT-2 inhibitor (SGLT-2i) therapy, met the primary endpoint in a phase 3 trial in patients with type 2 diabetes.
Novartis announced new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab).
Verona Pharma said that the first part of a two-part phase 2 trial of ensifentrine in a dry powder inhaler (DPI) formulation for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) has yielded positive interim efficacy and safety data.
Shield Therapeutics said that its oral ferric iron therapy Feraccru proved to be non-inferior to Ferinject (ferric carboxymaltose or FCM), a widely used intravenously delivered iron replacement therapy, in the AEGIS-H2H non-inferiority study.
Horizon Pharma plc (Nasdaq: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.